Denosumab is an injectable medication used in this clinical trial to help with the healing of bone fractures and to reduce foot deformities in patients with diabetes who have a condition known as Charcot foot. The trial aims to see if a single injection of denosumab can improve the healing process of bone fractures and reduce the time needed for wearing a total contact cast. This medication works by targeting a specific protein involved in bone breakdown, potentially leading to stronger bones and faster recovery.

Charcot Foot – Charcot foot is a condition that affects the bones, joints, and soft tissues of the foot or ankle, leading to inflammation and weakening. It often occurs in people with significant nerve damage, such as those with diabetes. The disease progresses through stages, starting with redness, warmth, and swelling, followed by bone and joint dislocation or fractures. Over time, the foot may become deformed, leading to changes in its shape and structure. This can result in difficulty walking and increased risk of ulcers or infections. Early detection and management are crucial to prevent severe deformities.

Diabetes – Diabetes is a chronic condition characterized by high levels of sugar in the blood due to the body’s inability to produce or effectively use insulin. It primarily includes two main types: Type 1, where the body does not produce insulin, and Type 2, where the body becomes resistant to insulin. Over time, high blood sugar levels can lead to complications affecting the heart, kidneys, eyes, and nerves. The progression of diabetes can vary, with some individuals experiencing symptoms like increased thirst, frequent urination, and fatigue. Long-term management focuses on maintaining blood sugar levels within a target range. Lifestyle changes and monitoring are essential to manage the condition effectively.